Kevin Jones
Aliri Bioanalysis
Episode 291
Why caring is winning in the CRO space
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development and commercialisation lifecycle with Kevin Jones, CEO of Aliri Bioanalysis.
Your host, Raman Sehgal, discusses the pharma and biopharma ecosystem with Kevin, covering:
- His journey from working nights in the lab to leading global commercial and scientific teams
- Why flexibility, care and a consultative approach are critical differentiators for smaller specialist CROs competing against one stop shop providers
- What attracted him to Aliri Bioanalysis, and the appeal of joining a fast growing, private equity backed business, something he had not previously experienced
- How the role and perception of CROs has evolved over the last 30 years, including Kevin’s five principles for what clients value when selecting partners today
- How the market has begun to rebound after a difficult few years, and why he believes the industry is entering a new molecule renaissance
Kevin Jones is CEO of Aliri Bioanalysis, a contract research organisation supporting drug developers with regulated bioanalysis and PK/TK testing. He began his career running laboratories and has spent three decades leading large, multidisciplinary scientific teams across both GMP and GLP/clinical environments.
Kevin previously led Global Bioanalysis at Covance, now Labcorp, and served as Vice President and General Manager of Bioanalytical/ADME, Vaccine and Discovery Laboratories at Q² Solutions, part of IQVIA. His experience spans laboratory operations, global integration and strategic growth, with a particular focus on building service organisations that scale without compromising quality or the client experience.
Connect with him on LinkedIn.
Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
